<i>TOP2A</i> Amplification in Breast Cancer in the Absence of That of <i>HER-2</i>: Myth or Reality?

Lamy, Pierre‐Jean; Jacot, William

doi:10.1634/theoncologist.2011-0430

The Oncologist

2012

DOI: 10.1634/theoncologist.2011-0430

|View full text |Cite

TOP2A Amplification in Breast Cancer in the Absence of That of HER-2: Myth or Reality?

Pierre‐Jean Lamy¹,

William Jacot²

Abstract: Confusion between topoisomerase IIα gene amplification and topoisomerase mRNA overexpression is proposed as possibly leading to misinerpretation in a study by Glynn et al. published in an earlier issue of The Oncologist.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

2014

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas

Zheng

et al. 2014

Med Oncol

View full text Add to dashboard Cite

Topoisomerase 2α (Topo2A) is a key enzyme in replication. It functions as a cell proliferation and cell cycle-specific marker and it is identified mainly in the interphase nuclei of proliferating cells. Many studies have shown that Topo2A protein expression is up-regulated in various cancers including esophageal cancer. However, to date, no studies have adequately addressed the prognostic value of Topo2A in patients with resectable esophageal squamous cell carcinoma (ESCC). Therefore, we conducted a large-scale retrospective study investigating the expression of Topo2A and the clinicopathological characteristics or prognosis of ESCC patients. Eight hundred and twenty-nine specimens of ESCC from patients who underwent complete esophageal cancer resection were evaluated using an immunohistochemical assay. Among them, 404 (48.7 %) cases with a score >2 were determined to be positive for Topo2A expression. Topo2A overexpression was significantly associated with poorer differentiation (P = 0.007) and perineural invasion (P = 0.046). The median progression-free survival (PFS) of 319 patients with Topo2A-positive expression and 336 patients with Topo2A-negative expression was 19.5 and 26.5 months, respectively (P = 0.000). The overall survival (OS) in patients with and without Topo2A expression was 34.0 and 44.5 months, respectively (P = 0.002). In the multivariate analysis, Topo2A overexpression was identified as an independent prognostic factor for PFS (P = 0.001) and OS (P = 0.009). We determined that Topo2A overexpression was not only associated with poorer differentiation and perineural invasion, but it could also act as an independent risk factor for ESCC.

show abstract

Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas

Zheng

et al. 2014

Med Oncol

View full text Add to dashboard Cite

show abstract

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond

Jacot

Fiche²,

Zaman

et al. 2013

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

TOP2A Amplification in Breast Cancer in the Absence of That of HER-2: Myth or Reality?

Abstract: Confusion between topoisomerase IIα gene amplification and topoisomerase mRNA overexpression is proposed as possibly leading to misinerpretation in a study by Glynn et al. published in an earlier issue of The Oncologist.

Cited by 2 publications

References 11 publications

Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas

Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond

Contact Info

Product

Resources

About